Reach Us +441234923305


The Diabetic Obese Chronic Obstructive Pulmonary Disease Patient In Pulmonary Rehabilitation Programme: New Challenges And Opportunities For Pharmacists | 13353
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The diabetic obese chronic obstructive pulmonary disease patient in pulmonary rehabilitation programme: New challenges and opportunities for pharmacists

International Summit on Clinical Pharmacy & Dispensing

Mohammed Shamssain

Accepted Abstracts: Clinic Pharmacol Biopharmaceut

DOI: 10.4172/2167-065X.S1.004

The prevalence rates of Chronic Obstructive Pulmonary Disease (COPD) and obesity are increasing. The morbidity and mortality from COPD and obesity are also increasing. The presentation will involve description of standardized outpatient pulmonary rehabilitation (PR) programme for COPD patients, diabetes as a comorbidity in PR, smoking as a risk factor for diabetes, causes of COPD exacerbations and the pathophysiological basis of lung disease in diabetes. These will include individual instructions about their disease, teaching about bronchial hygiene, breathing retraining, physical reconditioning, individualized pharmacologic therapy, smoking and diabetes. We will explore and find answers to the following questions: does diabetes alter lung function?, does therapy for COPD exacerbate diabetes?, does exercise benefit glycemic control? and does exercise reduce inflammation in chronic disease?. We will focus on the pathophysiologic basis for diabetic lung, drugs used for COPD patients and exacerbation of diabetes, and glycemic control during PR. The final part of the presentation will cover the effect of exercise on systemic inflammation. The roles of pharmacist in management of the diabetic obese COPD patients participating in PR will be explored and the new challenges and opportunities for pharmacists will be discussed.
Mohammed Shamssain has completed his Ph.D. at Loughborough University in the United Kingdom and he has been teaching and doing research at many universities around the globe. He is the founder and the principle investigator of ISAAC Centre (the international Study of Asthma and Allergies in Childhood) for the north east of England. He has more than 100 publications and international presentations.